US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
EP0922111B1
(en)
*
|
1996-07-23 |
2004-12-01 |
Tanox Pharma B.V. |
Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
|
US6051228A
(en)
*
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
JP3581660B2
(ja)
|
1999-04-30 |
2004-10-27 |
ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー |
潜伏ウイルスの再活性化を予防しウイルスの複製を制御するための方法
|
EP1642596A3
(en)
*
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US8383081B2
(en)
*
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
EP1194167B1
(en)
*
|
1999-06-09 |
2009-08-19 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target b-cells
|
WO2001013945A1
(en)
*
|
1999-08-23 |
2001-03-01 |
Biocrystal Ltd. |
Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
|
EP1221973B1
(en)
*
|
1999-10-04 |
2007-05-30 |
Novartis Vaccines and Diagnostics, Inc. |
CD40 antagonist for treating psoriasis
|
EP1839674A1
(en)
*
|
1999-10-04 |
2007-10-03 |
Novartis Vaccines and Diagnostics, Inc. |
CD40 antagonist for treating psoriasis
|
US6849425B1
(en)
*
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
AU1590201A
(en)
*
|
1999-11-09 |
2001-06-06 |
Chiron Corporation |
Compositions and methods for treating autoimmune diseases and transplant rejections
|
GB0001448D0
(en)
|
2000-01-21 |
2000-03-08 |
Novartis Ag |
Organic compounds
|
GB0006398D0
(en)
*
|
2000-03-16 |
2000-05-03 |
Novartis Ag |
Organic compounds
|
CN1450912A
(zh)
*
|
2000-04-19 |
2003-10-22 |
泰诺士公司 |
用于治疗牛皮癣和其它炎性皮肤病的cd40拮抗剂
|
US20030059427A1
(en)
*
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
US7063845B2
(en)
|
2000-04-28 |
2006-06-20 |
Gemini Science, Inc. |
Human anti-CD40 antibodies
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
CN1592645A
(zh)
*
|
2000-09-18 |
2005-03-09 |
拜奥根Idec公司 |
使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
|
JP4679035B2
(ja)
*
|
2001-04-02 |
2011-04-27 |
ジェネンテック, インコーポレイテッド |
併用療法
|
EP2011802A3
(en)
*
|
2001-04-27 |
2009-04-15 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-CD40 monoclonal antibody
|
AU2002347404A1
(en)
*
|
2001-09-14 |
2003-04-01 |
Cytos Biotechnology Ag |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
AR039067A1
(es)
*
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
EP1455812A4
(en)
*
|
2001-11-26 |
2006-03-22 |
Chiron Corp |
TREATMENT OF ANTI-CD40 MONOCLONAL ANTIBODY FOR THE TREATMENT OF MULTIPLE SCLEROSIS
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
EP2865688A1
(en)
*
|
2002-03-01 |
2015-04-29 |
Immunomedics, Inc. |
Internalizing anti-CD74 antibodies and methods of use
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
AU2003300842A1
(en)
*
|
2002-12-09 |
2004-06-30 |
Tolerrx, Inc. |
Inducing tolerance in primates
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
JP5019881B2
(ja)
*
|
2003-11-04 |
2012-09-05 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
アンタゴニスト抗cd40モノクローナル抗体およびそれらを使用するための方法
|
US7312320B2
(en)
*
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
US7674884B2
(en)
*
|
2003-12-10 |
2010-03-09 |
Novimmune S.A. |
Neutralizing antibodies and methods of use thereof
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
WO2005092927A1
(en)
|
2004-03-23 |
2005-10-06 |
Biogen Idec Ma Inc. |
Receptor coupling agents and therapeutic uses thereof
|
US20090202986A1
(en)
*
|
2004-10-22 |
2009-08-13 |
Huse William D |
Methods of optimizing antibody variable region binding affinity
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
JP2008535841A
(ja)
*
|
2005-04-06 |
2008-09-04 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ctla4変異分子によるグラフト移植に関連する免疫不全の治療方法
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
EP2312315A1
(en)
*
|
2005-05-18 |
2011-04-20 |
Novartis AG |
Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
|
WO2006128103A2
(en)
|
2005-05-26 |
2006-11-30 |
Seattle Genetics, Inc. |
Humanized anti-cd40 antibodies and their methods of use
|
US7668387B2
(en)
*
|
2005-06-20 |
2010-02-23 |
Intel Corporation |
Selective local transient improvement and peaking for video sharpness enhancement
|
CN101282745B
(zh)
|
2005-07-25 |
2015-04-29 |
新兴产品开发西雅图有限公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
US20070202549A1
(en)
*
|
2005-09-14 |
2007-08-30 |
University Of Pittsburgh |
Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets
|
WO2007033369A2
(en)
*
|
2005-09-14 |
2007-03-22 |
University Of Pittsburgh |
Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets
|
US20080131914A1
(en)
*
|
2005-09-14 |
2008-06-05 |
Ahearn Joseph M |
Assessing risk of cerebrovascular thrombosis by measuring c4d
|
WO2007053767A1
(en)
|
2005-11-01 |
2007-05-10 |
Novartis Ag |
Uses of anti-cd40 antibodies
|
MX2008013508A
(es)
|
2006-04-21 |
2008-10-31 |
Novartis Ag |
Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
|
CN101479375B
(zh)
|
2006-05-03 |
2016-03-30 |
科罗拉多州立大学董事会 |
Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
|
EP1854810A1
(en)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
JP5118139B2
(ja)
*
|
2006-08-04 |
2013-01-16 |
バクスター・インターナショナル・インコーポレイテッド |
新規発症自己免疫性糖尿病を予防および/または逆転させるためのマイクロスフィアに基づく組成物
|
US20090074711A1
(en)
*
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
CL2008002083A1
(es)
*
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
|
TWI439286B
(zh)
|
2007-07-16 |
2014-06-01 |
Genentech Inc |
抗-cd79b抗體及免疫共軛物及使用方法
|
CA2713504A1
(en)
|
2008-01-31 |
2009-08-13 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
BRPI1009458A2
(pt)
*
|
2009-03-10 |
2016-03-01 |
Baylor Res Inst |
vacinas antivirais direcionadas às células de apresentação de antígeno
|
DK2406290T3
(en)
|
2009-03-10 |
2017-09-11 |
Baylor Res Inst |
CANCER VACCINES TARGETED FOR ANTIGEN PRESENTING CELLS
|
CA2787054A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
TWI494126B
(zh)
|
2010-03-31 |
2015-08-01 |
Boehringer Ingelheim Int |
抗cd40抗體
|
LT3789038T
(lt)
*
|
2010-05-14 |
2022-12-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
SI2683406T1
(sl)
|
2011-03-11 |
2019-10-30 |
Beth Israel Deconess Medical Center Inc |
Protitelesa ANTI-CD40 in njihova uporaba
|
LT2699601T
(lt)
|
2011-04-21 |
2018-03-26 |
Bristol-Myers Squibb Company |
Antikūnų polipeptidai, kurie antagonizuoja cd40
|
CN106928362B
(zh)
|
2011-04-29 |
2021-10-26 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
TWI585102B
(zh)
|
2011-10-13 |
2017-06-01 |
必治妥美雅史谷比公司 |
拮抗cd40l之抗體多肽
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
CN110066335B
(zh)
|
2012-10-30 |
2024-04-05 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
PL2900277T3
(pl)
|
2012-12-13 |
2022-05-16 |
Immunomedics, Inc. |
Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10286058B2
(en)
|
2014-01-13 |
2019-05-14 |
Baylor Research Institute |
Vaccines against HPV and HPV-related diseases
|
WO2015130416A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
EP3113796A1
(en)
|
2014-03-07 |
2017-01-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
JP6654187B2
(ja)
|
2014-08-12 |
2020-02-26 |
アリゲーター・バイオサイエンス・アーベー |
抗cd40抗体を用いた併用療法
|
BR112017005134A2
(pt)
*
|
2014-09-16 |
2017-12-12 |
Ubi Ip Holdings |
tratamento e cura funcional de infecção por hiv por anticorpos monoclonais para inibição de entrada de hiv competitiva mediada por cd
|
US20160082120A1
(en)
|
2014-09-23 |
2016-03-24 |
Genentech, Inc. |
METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
|
KR20170072884A
(ko)
|
2014-10-29 |
2017-06-27 |
시애틀 지네틱스, 인크. |
비-푸코실화된 항-cd40 항체의 용량 및 투여
|
CN113699116A
(zh)
|
2014-12-10 |
2021-11-26 |
明尼苏达大学董事会 |
用于治疗疾病的遗传修饰的细胞、组织和器官
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
EP3303395B1
(en)
|
2015-05-29 |
2019-12-11 |
AbbVie Inc. |
Anti-cd40 antibodies and uses thereof
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
PL3307322T3
(pl)
|
2015-09-04 |
2021-07-05 |
Primatope Therapeutics Inc. |
Humanizowane przeciwciała anty-cd40 i ich zastosowania
|
PE20181367A1
(es)
|
2015-09-30 |
2018-08-27 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
RU2725292C2
(ru)
|
2016-04-27 |
2020-06-30 |
Иммьюномедикс, Инк. |
Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
|
TWI793162B
(zh)
|
2016-06-20 |
2023-02-21 |
英商克馬伯有限公司 |
抗體
|
EP3600283A4
(en)
|
2017-03-27 |
2020-12-16 |
Immunomedics, Inc. |
TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
CN112566933B
(zh)
|
2018-07-20 |
2023-07-14 |
祐和医药科技(北京)有限公司 |
抗cd40抗体及其用途
|
US20200190163A1
(en)
*
|
2018-10-26 |
2020-06-18 |
Lijun Wu |
Humanized bcma-car-t cells
|
US20230192840A1
(en)
*
|
2018-12-28 |
2023-06-22 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Antibody and use thereof
|
CN111454364B
(zh)
*
|
2019-03-04 |
2021-03-02 |
北京天广实生物技术股份有限公司 |
结合cd40的抗体及其用途
|
CN117683133A
(zh)
*
|
2019-09-03 |
2024-03-12 |
百奥泰生物制药股份有限公司 |
一种抗tigit免疫抑制剂及应用
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业(上海)股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
CN111763259B
(zh)
*
|
2020-09-03 |
2020-12-15 |
北京百奥赛图基因生物技术有限公司 |
抗cd40抗体及其用途
|
CN117500816A
(zh)
|
2021-08-26 |
2024-02-02 |
映恩生物制药(苏州)有限公司 |
一种甾体化合物及其缀合物
|
EP4402174A1
(en)
*
|
2021-09-17 |
2024-07-24 |
Novartis AG |
Methods for prevention of graft rejection in xenotransplantation
|
WO2024107752A2
(en)
|
2022-11-15 |
2024-05-23 |
Onestone Therapeutics Llc |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|